Department of Surgical Oncology and General Surgery, The First Hospital of China Medical University, 155 North Nanjing Street, Heping District, Shenyang 110001, China; Key Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors (China Medical University), Ministry of Education, 155 North Nanjing Street, Heping District, Shenyang 110001, China.
Department of Surgical Oncology and General Surgery, The First Hospital of China Medical University, 155 North Nanjing Street, Heping District, Shenyang 110001, China; Key Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors (China Medical University), Ministry of Education, 155 North Nanjing Street, Heping District, Shenyang 110001, China.
Crit Rev Oncol Hematol. 2022 Mar;171:103622. doi: 10.1016/j.critrevonc.2022.103622. Epub 2022 Feb 3.
For advanced cancers of the digestive system, personalized, precise treatment can be life saving. With the development of next-generation sequencing technology, detection of fusion genes in solid tumors has become more extensive. Some fusion gene targeting therapies have been written into guidelines for digestive tract tumors, such as for neurotrophic receptor tyrosine kinase and fibroblast growth factor receptor 2. There are also many fusion genes being investigated as potential future therapeutic targets. This review focuses on the current detection methods for fusion genes, fusion genes written into the digestive system tumor guidelines, and potential fusion gene therapy targets in different organs to discuss the possibility of clinical treatments for these targets in digestive system cancers.
对于消化系统的晚期癌症,个性化、精准的治疗可以救命。随着下一代测序技术的发展,实体瘤中融合基因的检测变得更加广泛。一些融合基因靶向治疗已被写入消化道肿瘤指南,如神经生长因子受体酪氨酸激酶和成纤维细胞生长因子受体 2。还有许多融合基因正在被作为潜在的未来治疗靶点进行研究。本文综述了目前融合基因的检测方法、写入消化系统肿瘤指南的融合基因以及不同器官中潜在的融合基因治疗靶点,讨论了这些靶点在消化系统癌症中临床治疗的可能性。